Refractory Migraine Clinical Trial
Official title:
A Randomized, Placebo-control of Pulsed Electromagnetic Field Therapy as Preventive Treatment of Refractory Migraine
Verified date | August 2012 |
Source | Niyayesh Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ethics Committee |
Study type | Interventional |
Pulsed electromagnetic field (PEMF) as prophylactic treatment may prevent the attacks of migraine or decrease them even in the patients with refractory migraine.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 17 Years to 55 Years |
Eligibility |
Inclusion Criteria: Primary Diagnosis A. ICHD-II migraine or chronic migraine Refractory B. Headaches cause significant interference with function or quality of life despite modification of triggers, lifestyle factors, and adequate trials of acute and preventive medicines with established efficacy. 1. Failed adequate trails of preventive medicines, alone or in combination from at least 2 of 4 drug classes: - Beta-blockers - Anticonvulsants - Tricyclics - Calcium channel blockers 2. Failed adequate trials of abortive medicines from the following classes, unless contraindicated: - Both a triptan and DHE intranasal or injectable formulation - Either nonsteroidal anti-inflammatory drugs or combination analgesics - Adequate trial Period of time during which an appropriate dose of medicine is administered, typically at least 2 months at optimal or maximum-tolerated doses, unless terminated early due to adverse effects - Modifiers With or without medication overuse, as defined by ICHD-2 - With significant disability, as defined by MIDAS > 11 - [DHE = dihydroergotamine; ICHD = International Classification of Headache Disorders;MIDAS = Migraine Disability Assessment] - The prophylactic medications have been discontinued at least one month prior to enrollment Exclusion Criteria: - pregnancy - epilepsy - malignancy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Niyayesh clinic | Tehran |
Lead Sponsor | Collaborator |
---|---|
Niyayesh Clinic | Tehran University of Medical Sciences |
Iran, Islamic Republic of,
B Hatef, B Majdoleslam, M Toghae, F Hashemirad. The Prophylactic Treatment of PEMF in the Refractory Migraine Headache, Double-Blind, Parallel Placebo-Controlled Study. CEPHALALGIA 33(s8): 98-99, 2013
Boshra Hatef, Fahime Hashemirad, Gholam Hossein Meftahi, Leila Simorgh, Soodeh Razeghi Jahromi, Forough Rahimi, Mansoureh ToghaThe efficiency of pulsed electromagnetic field in refractory migraine headaches: a randomized, single-blinded, placebo-controlle
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MIDAS | migraine disability score | 6 months | Yes |
Primary | headache frequency | 4 months | Yes | |
Primary | headache duration | 4 months | Yes | |
Primary | headache intensity | 4 months | Yes | |
Secondary | medications | 4 months | Yes | |
Secondary | missed work | 4 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06462781 -
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment
|
Phase 2 | |
Completed |
NCT00660192 -
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
|
Phase 2/Phase 3 |